NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

IRD

Opus Genetics Inc

May 23 • 04:00PM ET

1.02

Dollar change +0.01
Percentage change 0.99	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI VXF IWC BSVO

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.94	Insider Own	33.93%	Shs Outstand	45.48M	Perf Week	0.00%
Market Cap	60.86M	Forward P/E	-	EPS next Y	-0.53	Insider Trans	0.55%	Shs Float	39.42M	Perf Month	27.50%
Income	-58.62M	PEG	-	EPS next Q	-0.19	Inst Own	22.78%	Short Float	0.26%	Perf Quarter	-5.56%
Sales	13.65M	P/S	4.46	EPS this Y	60.62%	Inst Trans	256.23%	Short Ratio	0.48	Perf Half Y	15.46%
Book/sh	0.11	P/B	9.15	EPS next Y	37.01%	ROA	-117.23%	Short Interest	0.10M	Perf Year	-41.04%
Cash/sh	0.70	P/C	1.46	EPS next 5Y	35.76%	ROE	-229.30%	52W Range	0.65 - 2.18	Perf YTD	-14.29%
Dividend Est.	-	P/FCF	-	EPS past 5Y	24.32%	ROI	-245.11%	52W High	-53.21%	Beta	-0.01
Dividend TTM	-	Quick Ratio	1.98	Sales past 5Y	1314.24%	Gross Margin	-	52W Low	56.92%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	1.98	EPS Y/Y TTM	-308.39%	Oper. Margin	-265.88%	RSI (14)	59.88	Volatility	1.91% 3.70%
Employees	18	Debt/Eq	3.72	Sales Y/Y TTM	-28.19%	Profit Margin	-429.42%	Recom	1.00	Target Price	6.33
Option/Short	Yes / Yes	LT Debt/Eq	3.72	EPS Q/Q	16.56%	Payout	-	Rel Volume	0.48	Prev Close	1.01
Sales Surprise	41.03%	EPS Surprise	4.00%	Sales Q/Q	155.41%	Earnings	May 15 BMO	Avg Volume	211.80K	Price	1.02
SMA20	5.74%	SMA50	9.41%	SMA200	-9.27%	Trades		Volume	102,175	Change	0.99%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-11-25	Initiated	Craig Hallum	Buy	$6
Nov-13-24	Resumed	H.C. Wainwright	Buy	$8

May-15-25 09:15AM	Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update (GlobeNewswire)
May-14-25 06:55PM	Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-13-25 08:45AM	Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-12-25 08:00AM	Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May (GlobeNewswire)
09:25AM	Loading…
May-08-25 09:25AM	Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-06-25 08:00AM	Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate (GlobeNewswire)
May-05-25 08:00AM	Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision (GlobeNewswire)
May-02-25 10:00AM	Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline (Zacks)
Apr-15-25 10:36AM	PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath (GlobeNewswire)
Apr-11-25 03:47PM	Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns (GlobeNewswire)
Apr-08-25 08:00AM	Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases (GlobeNewswire) -11.50%
Apr-07-25 08:00AM	Opus Genetics Files Definitive Proxy Statement and Sends Letter to Stockholders Highlighting the Company's Transformation and Progress (GlobeNewswire)
Apr-02-25 08:00AM	Opus Genetics to Participate in Upcoming Investor Conference in April (GlobeNewswire)
Mar-31-25 08:20AM	Opus Genetics Announces Financial Results for Full Year 2024 (GlobeNewswire)
05:03PM	Loading…
Mar-21-25 05:03PM	Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics (GlobeNewswire) +9.57% -8.73%
09:30AM	Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX (GlobeNewswire)
09:11AM	Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million (GlobeNewswire)
Mar-19-25 03:56PM	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-05-25 08:00AM	Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting (GlobeNewswire)
Feb-26-25 08:00AM	Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs (GlobeNewswire)
Feb-18-25 07:30AM	Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program (GlobeNewswire)
Feb-07-25 09:15AM	Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc. (GlobeNewswire) -5.74%
Dec-19-24 08:00AM	Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy (GlobeNewswire) +18.93%
Dec-03-24 08:00AM	Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024 (GlobeNewswire) +5.22%
Nov-14-24 06:40AM	Opus Genetics reinstated with a Buy at H.C. Wainwright (TipRanks)
Nov-12-24 08:00AM	Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update (GlobeNewswire)
07:59AM	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-25-24 12:00PM	The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics (PR Newswire)
Oct-23-24 05:31PM	Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics (TipRanks) -12.03%
04:05PM	Loading…
Oct-22-24 04:05PM	Ocuphire Pharma Announces Acquisition of Opus Genetics (GlobeNewswire)
Sep-30-24 08:00AM	Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology (GlobeNewswire)
Sep-05-24 08:43PM	UPDATE Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia (GlobeNewswire)
08:00AM	Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia (GlobeNewswire)
Aug-13-24 08:00AM	Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update (GlobeNewswire) -20.85%
Aug-08-24 08:00AM	Ocuphire Pharma to Present at Two Investor Conferences in August (GlobeNewswire) +6.10%
Jul-10-24 08:00AM	Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July (GlobeNewswire) +6.45%
Jun-06-24 07:57AM	Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June (GlobeNewswire)
May-10-24 01:53PM	OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -12.24%
08:00AM	Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update (GlobeNewswire)
May-06-24 08:00AM	Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting (GlobeNewswire)
May-03-24 08:00AM	Ocuphire Pharma to Present at the Aegis Virtual Conference (GlobeNewswire) +7.57%
Apr-22-24 08:00AM	Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting (GlobeNewswire) -8.76%
Apr-11-24 10:03AM	First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery (GlobeNewswire)
Apr-01-24 07:14AM	Ocuphire Announces the U.S. Commercial Launch of RYZUMVl (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris (GlobeNewswire) +10.95%
Mar-15-24 11:53AM	OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
Mar-09-24 01:09PM	12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Mar-08-24 08:00AM	Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update (GlobeNewswire) -16.39%
Mar-04-24 08:18AM	Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-23-24 08:00AM	Ocuphire Pharma to Present in the BIO CEO & Investor Conference (GlobeNewswire)
Feb-15-24 04:10PM	Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-14-24 08:00AM	Ocuphire Pharma Strengthens Leadership Team with Key Appointments (GlobeNewswire)
Feb-05-24 08:00AM	Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference (GlobeNewswire)
Jan-24-24 04:10PM	Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-11-24 07:41AM	Here's Why You Should Invest in Ocuphire Pharma (OCUP) Now (Zacks) -7.81%
Jan-04-24 08:00AM	Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions (GlobeNewswire)
Nov-30-23 08:00AM	Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII (GlobeNewswire) +11.31%
Nov-27-23 04:38PM	Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer (GlobeNewswire)
Nov-13-23 08:00AM	Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update (GlobeNewswire)
Nov-02-23 08:00AM	Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy (GlobeNewswire)
Nov-01-23 04:52PM	Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:05AM	Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director (GlobeNewswire)
Oct-26-23 08:00AM	Ocuphire Pharma to Present at AAO 2023 and Eyecelerator Retina Showcase (GlobeNewswire)
Oct-06-23 08:00AM	Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October (GlobeNewswire)
Sep-27-23 08:00AM	Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents (PR Newswire) -5.97%
08:00AM	Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents (GlobeNewswire)
Sep-11-23 09:41AM	Ocuphire Pharma to Participate in Three Upcoming Investment Bank Conferences (GlobeNewswire)
Sep-07-23 09:00AM	Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September (GlobeNewswire)
Aug-28-23 08:00AM	Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposium (GlobeNewswire)
Aug-11-23 08:00AM	Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update (GlobeNewswire)
Aug-08-23 08:00AM	Ocuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference in August (GlobeNewswire)
Jul-26-23 08:00AM	Ocuphire to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit (GlobeNewswire)
Jul-10-23 05:19PM	Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-27-23 08:00AM	Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Associations Annual Conference (GlobeNewswire)
Jun-21-23 08:00AM	Ocuphire Announces Late Breaking Presentation on APX3330 ZETA-1 Clinical Data at American Diabetes Association Annual Conference (GlobeNewswire)
Jun-12-23 08:00AM	Ocuphire Presents APX3330 ZETA-1 Data at Clinical Trials at the Summit (CTS) 2023 (GlobeNewswire)
May-24-23 04:05PM	Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.20%
May-15-23 08:00AM	Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update (GlobeNewswire) -16.75%
May-02-23 08:30AM	Ocuphire Announces APX3330 and Nyxol® Data Presentations at ASCRS 2023 and Eyecelerator (GlobeNewswire) -8.31%
Apr-25-23 08:00AM	Ocuphire Provides Corporate Update and Reiterates Previous Guidance on Clinical Programs (GlobeNewswire) -7.66%
Apr-21-23 08:00AM	Ocuphire Appoints Rick Rodgers as Interim Chief Executive Officer (GlobeNewswire) -16.07%
Mar-30-23 08:00AM	Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update (GlobeNewswire) +6.39%
Mar-23-23 08:00AM	Ocuphire Announces APX3330 and Nyxol® Data Presentations at ARVO 2023 Annual Meeting (GlobeNewswire)
Feb-16-23 08:30AM	Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetings (GlobeNewswire)
Feb-13-23 08:00AM	Ocuphire Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol® Eye Drops for Reversal of Mydriasis (GlobeNewswire) +14.94%
Jan-25-23 04:01PM	Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA (GlobeNewswire) -19.95%
Jan-09-23 07:00AM	Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia (GlobeNewswire) +7.26%
Dec-06-22 06:00AM	Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis (GlobeNewswire) -5.28%
Dec-05-22 08:30AM	Stock Pitch World Cup(TM), Educational Panels and 49 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on December 6-8, 2022 (ACCESSWIRE)
Nov-21-22 08:00AM	Ocuphire to Present at Five Upcoming Investor/Industry Conferences (GlobeNewswire)
Nov-07-22 04:05PM	Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances (GlobeNewswire) -5.02% +19.71%
Nov-04-22 04:30PM	Ocuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update (GlobeNewswire)
Nov-02-22 08:10AM	Ocuphire Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol® and Strategic Partnership with American Society of Ophthalmic Administrators (ASOA) (GlobeNewswire) -6.03%
Oct-24-22 08:56AM	Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting (GlobeNewswire)
Oct-07-22 07:00AM	Ocuphire Pharma to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference (GlobeNewswire)
Oct-06-22 09:27AM	Ocuphire Pharma Hosting Key Opinion Leader Event on Oral APX3330 for Diabetic Eye Disease (GlobeNewswire)
Sep-29-22 08:00AM	Ocuphire Expands Medical Advisory Board with Seven New KOLs and Strengthens Leadership Team (GlobeNewswire)
Sep-27-22 09:05AM	60+ Companies to Present at the 2nd Annual MicroCap Rodeo - Windy City Roundup Conference on October 12th - 13th, 2022 in Chicago (ACCESSWIRE)
Sep-15-22 07:00AM	Ocuphire Announces Upcoming Presentations at European Forum 2022, Eyecelerator@AAO 2022 and the American Academy of Ophthalmology 2022 Annual Meeting (GlobeNewswire)

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Magrath George	Chief Executive Officer	Dec 26 '24	Buy	0.98	100,000	97,600	599,150	Dec 30 04:26 PM
YERXA BENJAMIN R	President	Nov 21 '24	Buy	0.98	10,000	9,834	342,800	Nov 25 04:18 PM
Magrath George	Chief Executive Officer	Nov 15 '24	Buy	1.01	90,294	91,215	483,244	Nov 19 04:08 PM
Magrath George	Chief Executive Officer	Nov 18 '24	Buy	1.02	9,706	9,943	492,950	Nov 19 04:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IRD

Opus Genetics Inc

Upgrade your FINVIZ experience